Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes
Apostolia Papalexandri(G. Papanikolaou General Hospital), Ioanna Sakellari(G. Papanikolaou General Hospital), Christos Demosthenous(G. Papanikolaou General Hospital), Eleni Gavriilaki(Aristotle University of Thessaloniki), Fotini S. Kika(G. Papanikolaou General Hospital), Michalis Iskas(G. Papanikolaou General Hospital), Ioannis Batsis(G. Papanikolaou General Hospital), Αchilles Anagnostopoulos(G. Papanikolaou General Hospital), Anna Vardi(G. Papanikolaou General Hospital), Evangelia Yannaki(G. Papanikolaou General Hospital), Nikolaos Kotsiou(Aristotle University of Thessaloniki), Natassa Constantinou(G. Papanikolaou General Hospital), Tasoula Touloumenidou(G. Papanikolaou General Hospital), Despina Mallouri(G. Papanikolaou General Hospital), Panagiota Zerva(American Institute of Biological Sciences)
Cited by 6
Related Papers
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
|Blood|2011|178
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
|Leukemia|2021|94
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL
|Blood|2013|93
Genetic prediction of ICU hospitalization and mortality in COVID‐19 patients using artificial neural networks
|Journal of Cellular and Molecular Medicine|2022|90
Genetic justification of severe COVID-19 using a rigorous algorithm
|Clinical Immunology|2021|63